BridgeMD
Cannabidiol for treatment of non-affective psychosis and cannabis use
EU CTIS ID: 2024-517630-18-00
What this study is testing
To examine the efficacy of cannabidiol (CBD) for treatment of psychosis
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ICD-10 diagnosis of schizophrenia (DF20.X), paranoid psychosis (DF22.X), acute/intermittent psychotic disorder (DF23.X), schizoaffective psychosis (DF25.X), other/not specified nonorganic psychotic disorder (DF28/DF29), or cannabis induced psychotic disorder (DF12.5)
- PANSS ≥ 60 and score of ≥ 4 on ≥ 2 PANSS-Positive subscale items: Delusions (P1), conceptual disorganization (P2), hallucinatory behaviour (P3), grandiosity (P5), suspiciousness (P6)
- Lifetime cannabis use
- Age 18-45 years
- Female patients of childbearing potential need to utilize a proper method of contraception
You likely can't join if
- Treatment resistance as defined by treatment (ever) with clozapine
- Dependence syndrome of alcohol or psychoactive substances other than cannabis (DF1X.2 other than DF12.2)
- Psychotic disorder induced by alcohol or psychoactive substances other than cannabis (DF1X.5 other than DF12.5)
- Treatment with a long-acting injectable antipsychotic within the past month (or corresponding to the usual interval between two injections)
- Treatment with an oral antipsychotic within the past 7 days
- Use of self-administered CBD products during the trial
See the full eligibility criteria
- ICD-10 diagnosis of schizophrenia (DF20.X), paranoid psychosis (DF22.X), acute/intermittent psychotic disorder (DF23.X), schizoaffective psychosis (DF25.X), other/not specified nonorganic psychotic disorder (DF28/DF29), or cannabis induced psychotic disorder (DF12.5)
- PANSS ≥ 60 and score of ≥ 4 on ≥ 2 PANSS-Positive subscale items: Delusions (P1), conceptual disorganization (P2), hallucinatory behaviour (P3), grandiosity (P5), suspiciousness (P6)
- Lifetime cannabis use
- Age 18-45 years
- Female patients of childbearing potential need to utilize a proper method of contraception
- Treatment resistance as defined by treatment (ever) with clozapine
- Dependence syndrome of alcohol or psychoactive substances other than cannabis (DF1X.2 other than DF12.2)
- Psychotic disorder induced by alcohol or psychoactive substances other than cannabis (DF1X.5 other than DF12.5)
- Treatment with a long-acting injectable antipsychotic within the past month (or corresponding to the usual interval between two injections)
- Treatment with an oral antipsychotic within the past 7 days
- Use of self-administered CBD products during the trial
- Patients involuntarily admitted
- Pregnancy or lactation
- Severe physical illness that might influence the ability to comply with the protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.